SCHEMBL13811890

SCHEMBL13811890

COc1ccc2cc(-c3n[nH]c4ccc(-c5nc(CO)n[nH]5)cc34)ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 1/20 0.46
TTK P33981 1/20 0.46
ITK Q08881 4/20 0.43
BTK Q06187 1/20 0.42
MAP2K4 P45985 3/20 0.42
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
PRKAG1 P54619 1/20 0.42
PRKAA1 Q13131 1/20 0.42
PRKAB1 Q9Y478 1/20 0.42
DCUN1D1 Q96GG9 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MAPK1 P28482 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
MAPKAPK3 Q16644 1/20 0.41
MAPK6 Q16659 1/20 0.41
TEK Q02763 1/20 0.41
LRRK2 Q5S007 1/20 0.41
CDK4 P11802 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089492 0.89 TTK (0.46) GRK6TTKITKBTKPRKAG1
SCHEMBL13890795 0.83 GRK6 (0.37) GRK6TTKITKBTKPRKAG1
SCHEMBL13812021 0.83 TTK (0.39) GRK6TTKITKPRKAG1PRKAA1
SCHEMBL4084647 0.83 CLK2 (0.46) TTKITKRAB9AMAPK1LRRK2
SCHEMBL4085679 0.82 LRRK2 (0.42) GRK6TTKITKLRRK2HTR2A
SCHEMBL13811892 0.81 LRRK2 (0.50) GRK6TTKITKPRKAG1PRKAA1
SCHEMBL4094963 0.81 CYP1A2 (0.49) GRK6TTKITKBTKPRKAG1
SCHEMBL13812153 0.80 GSK3B (0.47) TTKLRRK2CDK2GSK3BDYRK1A
SCHEMBL4084381 0.80 GSK3B (0.46) GRK6ITKLRRK2CDK2GSK3B
SCHEMBL13812149 0.80 LRRK2 (0.39) GRK6TTKITKLRRK2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 GRK6 762/4885TTK 401/4885ITK 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.